Complete Filing Data
KESTRA MEDICAL TECHNOLOGIES, LTD. reported Stockholders Equity Including Portion Attributable To Noncontrolling Interest of -$117.58 million for FY2023.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean KESTRA MEDICAL TECHNOLOGIES, LTD. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Net Income * | -$113.8M | -$94.1M |
| Selling General And Administrative Expense | $114.9M | $69.9M |
| Revenue From Contract With Customer Excluding Assessed Tax | $59.8M | $27.8M |
| Research And Development Expense | $15.7M | $15.5M |
| Other Nonoperating Income Expense | -$2.8M | -$2.8M |
| Operating Income Loss | -$106.4M | -$85.1M |
| Operating Expenses | $130.6M | $85.4M |
| Net Income Loss Available To Common Stockholders Diluted | -$126.1M | -$100.8M |
| Net Income Loss Available To Common Stockholders Basic | -$126.1M | -$100.8M |
| Interest Expense Nonoperating | $7.7M | $6.2M |
| Income Tax Expense Benefit | $135.0K | $24.0K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$113.7M | -$94.1M |
| Gross Profit | $24.2M | $362.0K |
| Cost Of Goods And Services Sold | $35.6M | $27.5M |
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | ||
| Income Taxes Paid Net | $83.0K | -$30.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|
| Net Income * | -$34.2M | -$32.8M | -$25.8M | -$21.5M | -$20.4M | -$19.9M |
| Selling General And Administrative Expense | $42.7M | $38.3M | $33.7M | $23.8M | $21.5M | $19.2M |
| Revenue From Contract With Customer Excluding Assessed Tax | $24.6M | $22.6M | $19.4M | $15.1M | $14.7M | $12.8M |
| Research And Development Expense | $5.0M | $4.9M | $4.0M | $3.4M | $3.5M | $3.4M |
| Other Nonoperating Income Expense | $359.0K | -$891.0K | $2.8M | $15.0K | -$40.0K | -$48.0K |
| Operating Income Loss | -$34.8M | -$31.8M | -$28.9M | -$20.6M | -$19.1M | -$18.4M |
| Operating Expenses | $47.7M | $43.2M | $37.7M | $27.1M | $25.0M | $22.6M |
| Net Income Loss Available To Common Stockholders Diluted | -$34.2M | -$32.8M | -$25.8M | -$24.8M | -$23.7M | -$22.3M |
| Net Income Loss Available To Common Stockholders Basic | -$34.2M | -$32.8M | -$25.8M | -$24.8M | -$23.7M | -$22.3M |
| Interest Expense Nonoperating | $1.9M | $1.9M | $1.9M | $1.8M | $2.3M | $1.9M |
| Income Tax Expense Benefit | $35.0K | $34.0K | $33.0K | $18.0K | $8.0K | $7.0K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$34.1M | -$32.8M | -$25.8M | -$21.7M | -$20.6M | -$20.3M |
| Gross Profit | $12.9M | $11.4M | $8.9M | $6.5M | $5.8M | $4.2M |
| Cost Of Goods And Services Sold | $11.6M | $11.1M | $10.5M | $8.5M | $8.9M | $8.6M |
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | -$34.2M | -$32.8M | -$25.8M | -$21.8M | -$20.6M | -$20.3M |
| Income Taxes Paid Net | -$39.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -$117.6M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $15.3M | ||
| Cash And Cash Equivalents At Carrying Value | $8.2M | ||
| Common Stock Value | $19.9M | ||
| Operating Lease Right Of Use Asset | $2.3M | ||
| Retained Earnings Accumulated Deficit | -$406.4M | ||
| Restricted Cash Noncurrent | $334.0K | ||
| Restricted Cash | $334.0K | $334.0K | |
| Receivables Net Current | $2.0M | ||
| Purchases Of Property And Equipment In Accrued Liabilities Accounts Payable | $7.0M | $11.1M | |
| Provision For Uncollectible Accounts Receivable | $2.7M | $500.0K | |
| Property Plant And Equipment Net | $26.1M | ||
| Prepaid Expense And Other Assets Current | $1.4M | ||
| Other Liabilities Noncurrent | $76.0K | ||
| Other Assets Noncurrent | $607.0K | ||
| Operating Lease Liability Noncurrent | $2.6M | ||
| Non Cash Lease Expense | $416.0K | $729.0K | |
| Long Term Debt Noncurrent | $42.5M | ||
| Liabilities Current | $33.0M | ||
| Liabilities And Stockholders Equity | $45.9M | ||
| Liabilities | $78.2M | ||
| Gain Loss On Sale Of Property Plant Equipment | -$2.1M | -$1.1M | |
| Deposits Assets Noncurrent | $1.7M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $229.3M | -$6.7M | |
| Assets Current | $14.9M | ||
| Assets | $45.9M | ||
| Additional Paid In Capital Common Stock | $177.1M | ||
| Accrued Liabilities Current | $9.1M | ||
| Accounts Payable Current | $23.9M | ||
| Temporary Equity Stock Issued During Period Shares New Issues | |||
| Preferred Stock Dividends Income Statement Impact | $12.3M | $6.7M | |
| Operating Lease Liability Current |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | $288.0M | $164.1M | $184.2M | $205.4M | -$257.9M | -$236.5M | -$216.5M | -$209.4M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $291.7M | $175.8M | $201.5M | $237.9M | $54.7M | $77.3M | $100.3M | $8.6M |
| Cash And Cash Equivalents At Carrying Value | $291.3M | $175.4M | $201.2M | $237.6M | $54.4M | $76.9M | $100.0M | |
| Common Stock Value | $58.3M | $51.4M | $51.3M | $51.3M | $100.00 | |||
| Operating Lease Right Of Use Asset | $3.4M | $1.6M | $2.0M | $2.1M | ||||
| Retained Earnings Accumulated Deficit | -$613.0M | -$578.9M | -$546.1M | -$520.2M | ||||
| Restricted Cash Noncurrent | $334.0K | $334.0K | $334.0K | $334.0K | ||||
| Restricted Cash | $334.0K | $334.0K | $334.0K | $334.0K | $334.0K | $334.0K | ||
| Receivables Net Current | $12.7M | $10.4M | $9.2M | $8.1M | ||||
| Purchases Of Property And Equipment In Accrued Liabilities Accounts Payable | $6.9M | $8.5M | ||||||
| Provision For Uncollectible Accounts Receivable | $613.0K | $706.0K | ||||||
| Property Plant And Equipment Net | $53.8M | $45.9M | $40.4M | $34.8M | ||||
| Prepaid Expense And Other Assets Current | $3.2M | $2.7M | $3.4M | $3.1M | ||||
| Other Liabilities Noncurrent | $140.0K | $140.0K | $140.0K | $140.0K | ||||
| Other Assets Noncurrent | $5.9M | $1.2M | $1.1M | $1.2M | ||||
| Operating Lease Liability Noncurrent | $4.3M | $2.9M | $3.1M | $3.0M | ||||
| Non Cash Lease Expense | $61.0K | $152.0K | ||||||
| Long Term Debt Noncurrent | $42.3M | $41.9M | $41.5M | $41.1M | ||||
| Liabilities Current | $42.9M | $35.8M | $32.3M | $38.0M | ||||
| Liabilities And Stockholders Equity | $379.3M | $246.7M | $266.3M | $295.7M | ||||
| Liabilities | $91.4M | $82.6M | $82.1M | $90.3M | ||||
| Gain Loss On Sale Of Property Plant Equipment | -$280.0K | -$255.0K | ||||||
| Deposits Assets Noncurrent | $1.8M | $1.9M | $1.8M | $2.0M | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$36.4M | $91.7M | ||||||
| Assets Current | $314.1M | $195.4M | $220.7M | $255.3M | ||||
| Assets | $379.3M | $246.7M | $266.3M | $295.7M | ||||
| Additional Paid In Capital Common Stock | $842.7M | $691.5M | $678.9M | $674.3M | ||||
| Accrued Liabilities Current | $18.9M | $15.5M | $13.7M | $13.8M | ||||
| Accounts Payable Current | $24.0M | $20.2M | $18.6M | $24.0M | ||||
| Temporary Equity Stock Issued During Period Shares New Issues | 0.00 | |||||||
| Preferred Stock Dividends Income Statement Impact | $3.3M | $3.3M | $2.4M | |||||
| Operating Lease Liability Current | $10.0K | $53.0K | $36.0K | $187.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Share Based Compensation | $24.3M | $1.5M |
| Payments To Acquire Property Plant And Equipment | $22.9M | $12.2M |
| Net Cash Provided By Used In Operating Activities | -$77.6M | -$72.2M |
| Net Cash Provided By Used In Investing Activities | -$23.3M | -$12.2M |
| Net Cash Provided By Used In Financing Activities | $330.3M | $77.7M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $1.9M | -$331.0K |
| Increase Decrease In Other Noncurrent Assets | -$40.0K | $10.0K |
| Increase Decrease In Operating Lease Liability | $370.0K | -$469.0K |
| Increase Decrease In Disposable Medical Equipment Supplies | -$3.4M | -$1.2M |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | $4.6M | $371.0K |
| Increase Decrease In Accounts Receivable | $8.8M | $2.5M |
| Increase Decrease In Accounts Payable | $2.8M | $7.3M |
| Depreciation Depletion And Amortization | $8.0M | $11.6M |
| Payments Of Stock Issuance Costs | $3.2M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q3 2024 |
|---|---|---|
| Share Based Compensation | $4.6M | $377.0K |
| Payments To Acquire Property Plant And Equipment | $8.2M | $7.0M |
| Net Cash Provided By Used In Operating Activities | -$26.3M | -$17.5M |
| Net Cash Provided By Used In Investing Activities | -$8.2M | -$7.0M |
| Net Cash Provided By Used In Financing Activities | -$1.9M | $116.3M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$140.0K | $389.0K |
| Increase Decrease In Other Noncurrent Assets | -$10.0K | -$10.0K |
| Increase Decrease In Operating Lease Liability | -$138.0K | $22.0K |
| Increase Decrease In Disposable Medical Equipment Supplies | -$460.0K | -$599.0K |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -$860.0K | $140.0K |
| Increase Decrease In Accounts Receivable | $1.8M | $2.9M |
| Increase Decrease In Accounts Payable | -$2.9M | $2.3M |
| Depreciation Depletion And Amortization | $2.0M | $2.4M |
| Payments Of Stock Issuance Costs | $3.2M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 24.6M | 19.9M |
| Weighted Average Number Of Diluted Shares Outstanding | 24.6M | 19.9M |
| Earnings Per Share Diluted | $-5.13 | $-5.07 |
| Earnings Per Share Basic | $-5.13 | $-5.07 |
| Common Stock Shares Authorized | 5.0M | |
| Common Stock Shares Outstanding | 105.8K | |
| Common Stock Shares Issued | 105.8K | |
| Common Stock Par Or Stated Value Per Share | $0.01 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 55.8M | 51.4M | 51.3M | 19.9M | 19.9M | 19.9M | |
| Weighted Average Number Of Diluted Shares Outstanding | 55.8M | 51.4M | 51.3M | 19.9M | 19.9M | 19.9M | |
| Earnings Per Share Diluted | $-0.61 | $-0.64 | $-0.50 | $-1.25 | $-1.19 | $-1.12 | |
| Earnings Per Share Basic | $-0.61 | $-0.64 | $-0.50 | $-1.25 | $-1.19 | $-1.12 | |
| Common Stock Shares Authorized | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | ||
| Common Stock Shares Outstanding | 58.3M | 51.4M | 51.3M | 51.3M | 100.00 | ||
| Common Stock Shares Issued | 58.3M | 51.4M | 51.3M | 51.3M | 100.00 | ||
| Common Stock Par Or Stated Value Per Share | $1.00 | $1.00 | $1.00 | $1.00 | $1.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $24.3M | $1.5M |
| Investment Income Interest | $3.2M | |
| Adjustments To Additional Paid In Capital Deemed Dividend For Payments To Third Party On Behalf Of Stockholder | $4.9M | $799.0K |
| Refund Of Deposits For Medical Rental Equipment | $283.0K | $285.0K |
| Interest Paid Net | $4.9M | $3.6M |
| Disposable Medical Equipment Supplies Current | $3.3M | |
| Deposits For Medical Rental Equipment | $655.0K | $288.0K |
| Amortization Of Financing Costs And Discounts | $1.4M | $610.0K |
| Warrants And Rights Outstanding |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $10.1M | $8.7M | $4.6M | $459.0K | $1.1M | $377.0K | |
| Investment Income Interest | $2.2M | $1.8M | $2.2M | $628.0K | $878.0K | $37.0K | |
| Adjustments To Additional Paid In Capital Deemed Dividend For Payments To Third Party On Behalf Of Stockholder | $320.0K | $50.0K | $575.0K | $4.2M | |||
| Refund Of Deposits For Medical Rental Equipment | $37.0K | $23.0K | |||||
| Interest Paid Net | $1.4M | $1.2M | |||||
| Disposable Medical Equipment Supplies Current | $6.8M | $6.9M | $6.8M | $6.6M | |||
| Deposits For Medical Rental Equipment | $103.0K | $20.0K | |||||
| Amortization Of Financing Costs And Discounts | $469.0K | $200.0K | |||||
| Warrants And Rights Outstanding | $1.7M | $2.0M | $5.2M | $8.1M |
Most recent annual filing with the SEC: July 17, 2025
Data sourced from SEC EDGAR public filings as of August 9, 2026.